Breast cancer

Novel small molecule blocks breast and ovarian cancer in mice

Novel small molecule blocks breast and ovarian cancer in mice

Anika Sharma

A groundbreaking discovery in the fight against breast and ovarian cancers has emerged from the laboratories of Baylor College of ...

ESMO 2023: Keytruda + Chemo Boosts pCR in ER+/HER2– Breast Cancer

Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2– Breast Cancer Treatment (ESMO 2023)

Anika Sharma

ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...

Hologic Partners with Nonprofit for 'Know Your Lemons' Breast Cancer Education Drive

Hologic Partners with Nonprofit for ‘Know Your Lemons’ Breast Cancer Education Drive

Anika Sharma

In observance of Breast Cancer Awareness Month, Hologic is intensifying its efforts to promote breast health. The Massachusetts-based company, known ...

Galderma Initiates Breast Cancer Campaign Focusing on Aesthetic Solutions for Survivor Confidence

Galderma Initiates Breast Cancer Campaign Focusing on Aesthetic Solutions for Survivor Confidence

Anika Sharma

In observance of Breast Cancer Awareness Month this October, Galderma, a specialist in dermatology, has partnered with the National Breast ...

Estée Lauder’s Pink Ribbon Campaign for Breast Cancer

Estée Lauder’s Pink Ribbon Campaign for Breast Cancer

Anika Sharma

With a historic legacy of three decades of unwavering dedication to breast cancer awareness, the Estée Lauder Companies are set ...

NICE rejects Enhertu for HER2-low breast cancer over cost concerns

NICE rejects Enhertu for HER2-low breast cancer over cost concerns

Anika Sharma

The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...

dato-dxd breast cancer trial results, astrazeneca daiichi breast cancer adc, dato-dxd vs trodelvy breast cancer, dato-dxd fda approval status, dato-dxd progression-free survival breast cancer, dato-dxd safety and efficacy breast cancer, dato-dxd her2-low breast cancer

AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead

Anika Sharma

AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...

robotic surgery, FDA, breast cancer, FDA clearance, Insight Medbotics, MRI machine

FDA approves world’s first MRI-compatible breast biopsy robot

Anika Sharma

Insight Medbotics has achieved FDA clearance for what it claims to be the world’s first surgical robot designed to operate ...

Ibex Medical Analytics, Artificial intelligence, Cancer diagnostics, funding, Breast cancer

Ibex raises $55M to expand its AI-powered cancer diagnostics in the US and beyond

Anika Sharma

Ibex Medical Analytics, an Israeli startup specializing in Artificial intelligence-powered cancer diagnostics, has secured an impressive $55 million in funding ...

BioNTech, DualityBio, Breast Cancer, DB-1303, HER2-low breast cancer, Clinical trial initiation, Antibody-drug conjugate

BioNTech and DualityBio Advance Novel HER2-low Breast Cancer Drug to Phase III Trial

Anika Sharma

BioNTech, the renowned name behind the COVID-19 vaccine breakthrough, is venturing into uncharted territory with its licensed antibody-drug conjugate (ADC), ...

Tecentriq, Roche, Immunotherapy, PD-L1 inhibitor, lung cancer, bladder cancer, breast cancer, liver cancer

Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light

Anika Sharma

Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...

Seagen, Tukysa, Breast cancer, Antibody drug conjugates, Clinical Data, Pharma, Roche, Kadcyla, Enhertu, Pfizer, HER2

Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition

Anika Sharma

In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...

Trodelvy: A Breakthrough Drug for Triple-Negative Breast Cancer

Trodelvy: The New Hope for Breast Cancer Patients

SG Tylor

Trodelvy is a brand name for sacituzumab govitecan-hziy, a new type of drug that combines an antibody with a chemotherapy ...

Elacestrant: A Breakthrough Drug for Advanced Breast Cancer Gets EU Approval

CHMP Greenlights Elacestrant for Advanced Breast Cancer Treatment in the EU

SG Tylor

Source – Menarini Group A new treatment option for postmenopausal women with advanced or metastatic breast cancer has moved a ...

Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients

Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients

SG Tylor

Source – AstraZeneca  Enhertu (trastuzumab deruxtecan), a targeted antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, has received approval ...

In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex

In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex

SG Tylor

Source- Astrazeneca The US Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca’s New Drug Application ...

Roche's HER2 Powerhouse: Leading the Way in Breast Cancer Treatment

Roche’s HER2 Powerhouse: Leading the Way in Breast Cancer Treatment

SG Tylor

Breast cancer treatment was primarily based on the tumor’s location for most of the previous century, resulting in varying outcomes. ...